U.S FDA Deprioritises EUA Application for CoviDx
Filed with ASX · · 2 pages · English
SARASOTA, Fla. (22 September 2021)– Lumos Diagnostics(ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, has received correspondence from the U.S. Food and Drug Administration (FDA) indicating that the FDA has deprioritised Lumos’ request for Emergency Use Authorization (EUA) for the CoviDx™ SARS-CoV-2 Rapid Antigen Test (CoviDx™) and has ceased review of the EUA at this time
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- FY21 Full Year Results
- FY21 Full Year Results Investor Presentation
- FY21 Full Year Results Media Release
- FY21 Appendix 4E
Later from Lumos Diagnostics
- Economic Evaluation of FebriDx
- Update on Economic Evaluation of FebriDx
- Monthly Activities/Appendix 4C Cash Flow Report
- LDX received authorization to sell CoviDx in Canada
- Lumos Receives Initial Orders for CoviDx In Canada
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics